Lu-177 treatment for PSMA-positive metastatic prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a radioactive drug called Lutetium-177 (Lu-177) that targets and kills prostate cancer cells showing a specific marker (PSMA). It's for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, and who have already tried certain chemotherapy or cannot have it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have metastatic prostate cancer that still grows despite low testosterone levels (castration-resistant).
- You must have had treatment with docetaxel (chemotherapy) and at least one hormone therapy like abiraterone or enzalutamide, or you are unable to have docetaxel.
- A PSMA PET-CT scan must show that your tumors are PSMA-positive.
- You should be in generally good health, able to do daily activities (WHO performance status 0-2).
- Your blood counts, kidney, and liver function must be within safe limits.
- You must not have active spinal cord compression, blocked urine flow, or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
Hear when a new Metastatic Prostate Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.